-transparent.png){kind=logo}
Histidyl-proline-diketopiperazine (DKP) -- a stable degradation product of TRH -- has been shown to selectively inhibit prolactin secretion in vitro in rat pituitary tissue. In this study the effects of DKP on serum prolactin in intact and anaesthetized male rhesus monkeys and on TRH-stimulated prolactin levels have been investigated. In conscious monkeys 400 micrograms DKP significantly suppressed prolactin levels by 27%, and under ketamine anaesthesia, serum prolactin was suppressed in a dose-dependent manner by 150 and 400 micrograms DKP. The maximum prolactin response and the cumulative response to TRH (20 micrograms) was significantly and specifically inhibited by 400 micrograms DKP, while the lower dose was without effect. TSH levels were not affected by DKP in any instance. Hence DKP can specifically inhibit prolactin release in the rhesus monkey, and may be discussed as a possible regulatory factor in prolactin secretion.
G Brabant, and
E J Wickings, and
E Nieschlag
July 1978,
Nature,
G Brabant, and
E J Wickings, and
E Nieschlag
September 1979,
European journal of pharmacology,
G Brabant, and
E J Wickings, and
E Nieschlag
January 1982,
Clinical endocrinology,
G Brabant, and
E J Wickings, and
E Nieschlag
November 1989,
Nihon Naibunpi Gakkai zasshi,
G Brabant, and
E J Wickings, and
E Nieschlag
January 1981,
Peptides,
G Brabant, and
E J Wickings, and
E Nieschlag
May 1981,
European journal of pharmacology,
G Brabant, and
E J Wickings, and
E Nieschlag
March 1987,
The Journal of clinical investigation,
G Brabant, and
E J Wickings, and
E Nieschlag
November 1981,
Endocrinology,
G Brabant, and
E J Wickings, and
E Nieschlag
November 1985,
Endocrinology,
G Brabant, and
E J Wickings, and
E Nieschlag
May 1980,
Biochemical and biophysical research communications,
